North America Generic Drugs Market Size and Forecast (2021 - 2031) Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Molecule Type (Antidepressants, Antihistamines, Analgesics, Antibiotics, Antivirals, Diuretics, and Other Molecul

The North America generic drugs market is projected to grow significantly, reaching approximately USD 289.26 billion by 2031, up from USD 207.73 billion in 2024. This growth represents a compound annual growth rate (CAGR) of 4.9% from 2025 to 2031.

Executive Summary and Market Analysis

The generic drugs sector in North America is witnessing steady expansion, primarily driven by escalating healthcare costs, an increasing population, the expiration of patents for branded medications, and a rising demand for affordable treatment options. The United States, Canada, and Mexico are the primary contributors to this market, with the U.S. holding the largest share. By 2030, it is estimated that one in five Americans will be over the age of 65, which will heighten the demand for cost-effective treatments for chronic conditions such as diabetes, hypertension, and arthritis.

Government support and regulatory frameworks are also bolstering the market. Agencies like the U.S. Food and Drug Administration (FDA) have implemented accelerated approval pathways for generic drugs, facilitating quicker access to these medications without compromising safety or efficacy. This regulatory environment has made it easier for manufacturers to introduce generics into the market. Additionally, there is a strong focus on healthcare cost containment, with payers and policymakers advocating for the use of generics to lower overall healthcare spending. According to the Association for Accessible Medicines, generics accounted for 90% of prescriptions dispensed in the U.S. and 18% of total drug spending in 2023. The market is also characterized by increased competition and consolidation, as companies expand their portfolios through partnerships and acquisitions to meet the growing demand.

Market Segmentation Analysis

The North America generic drugs market can be segmented based on molecule type, indication, type, and distribution channel:

Molecule Type: The market is divided into several categories, including antidepressants, antihistamines, analgesics, antibiotics, antivirals, diuretics, and others. In 2024, the antibiotics segment held the largest market share.
Indication: The market is segmented into various indications such as metabolic diseases, cancer, immunology, respiratory disorders, cardiovascular disorders, neurology disorders, rare diseases, and others. The cancer segment was the largest in 2024.
Type: The market is further bifurcated into prescription and over-the-counter (OTC) drugs, with the prescription segment holding a larger share in 2024.
Distribution Channel: The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies leading in market share in 2024.

Market Outlook

Biosimilars are becoming increasingly important in the global generic drugs market, driven by several key trends. The expiration of patents for major biologic drugs has opened the door for biosimilars, which provide more affordable alternatives and help reduce healthcare costs. Regulatory bodies like the FDA and the European Medicines Agency (EMA) have established streamlined approval processes for biosimilars, facilitating their timely entry into the market. This has led to greater acceptance among healthcare providers, supported by real-world evidence and successful clinical trials that demonstrate their safety and efficacy. As more biologic patents expire, competition in the market is intensifying, prompting pharmaceutical companies to invest in biosimilar development. Furthermore, biosimilars are gaining traction in emerging markets, improving access to essential biologic treatments at lower costs.

The World Health Organization (WHO) has highlighted that noncommunicable diseases (NCDs) such as cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes are the leading causes of death and disability globally. In 2019, NCDs accounted for 41 million of the 55 million global deaths, representing 75% of all deaths that year. The burden of NCDs is expected to rise, with projections suggesting that by 2050, chronic diseases will account for 86% of the 90 million deaths annually, marking a 90% increase since 2019. This growing prevalence of chronic diseases underscores the urgent need for effective prevention and management strategies. Biosimilars play a crucial role by offering cost-effective treatment options, thereby enhancing access to necessary therapies and alleviating financial burdens on healthcare systems and patients.

Country Insights

The North America generic drugs market is comprised of the U.S., Canada, and Mexico, with the U.S. holding the largest market share in 2024. The U.S. generic drugs market is experiencing robust growth, driven by the increasing burden of chronic illnesses, cancer, and infectious diseases, alongside a push for affordable healthcare solutions. In 2024, approximately 2 million new cancer cases were diagnosed, highlighting the urgent need for cost-effective treatments. While innovative therapies such as therapeutic cancer vaccines and mRNA vaccines show promise, the affordability and accessibility provided by generic drugs remain essential for public health.

The U.S. biopharmaceutical industry, which includes generic manufacturers, is a global leader in innovation and scale, generating over USD 800 billion in direct output in 2022. The industry invested USD 141 billion in domestic research and development, representing a significant portion of U.S. industry-funded medical research.

Company Profiles

Key players in the North America generic drugs market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, and Glenmark Pharmaceuticals Ltd. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and meet consumer demands. Show more